{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:39:22Z","timestamp":1792179562833,"version":"4.4.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,4,12]],"date-time":"2016-04-12T00:00:00Z","timestamp":1460419200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s40618-016-0466-0","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T05:53:22Z","timestamp":1460613202000},"page":"1015-1021","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI"],"prefix":"10.1007","volume":"39","author":[{"given":"C.","family":"Sabbadin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Andrisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zermiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Don\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bordin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Ragazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Boscaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Ambrosini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Armanini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,12]]},"reference":[{"key":"466_CR1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1365-2265.1985.tb01090.x","volume":"23","author":"D Armanini","year":"1985","unstructured":"Armanini D, Karbowiak I, Goi A, Mantero F, Funder JW (1985) In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay. Clin Endocrinol 23:341\u2013347","journal-title":"Clin Endocrinol"},{"key":"466_CR2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1210\/jcem-51-3-429","volume":"51","author":"G Shapiro","year":"1980","unstructured":"Shapiro G, Evron S (1980) A novel use of spironolactone: treatment of hirsutism. J Clin Endocrinol Metabol 51:429\u2013432","journal-title":"J Clin Endocrinol Metabol"},{"key":"466_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/CLEP.S37559","volume":"6","author":"SM Sirmans","year":"2013","unstructured":"Sirmans SM, Pate KA (2013) Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol 6:1\u201313","journal-title":"Clin Epidemiol"},{"key":"466_CR4","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2265.2000.00982.x","volume":"52","author":"PM Spritzer","year":"2000","unstructured":"Spritzer PM, Lisboa KO, Mattiello S, Lhullier F (2000) Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol 52:587\u2013594","journal-title":"Clin Endocrinol"},{"key":"466_CR5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1210\/endo-97-1-52","volume":"97","author":"P Corvol","year":"1975","unstructured":"Corvol P, Michaud A, Menard J, Freifeld M, Mahoudeau J (1975) Antiandrogenic effect of spironolactones: mechanism of action. Endocrinology 97:52\u201358","journal-title":"Endocrinology"},{"key":"466_CR6","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1210\/jcem-41-4-777","volume":"41","author":"B Stripp","year":"1975","unstructured":"Stripp B, Taylor AA, Bartter FC, Gillette JR, Loriaux DL, Easley R, Menard RH (1975) Effect of Spironolactone on sex hormones in man. J Clin Endocrinol Metabol 41:777\u2013781","journal-title":"J Clin Endocrinol Metabol"},{"key":"466_CR7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0022-5347(17)57495-9","volume":"119","author":"S Baba","year":"1978","unstructured":"Baba S, Murai M, Jitsukawa S, Hata M, Tazaki H (1978) Antiandrogenic effects of spironolactone: hormonal and ultrastructural studies in dogs and men. J Urol 119:375\u2013380","journal-title":"J Urol"},{"key":"466_CR8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF03350556","volume":"6","author":"M Messina","year":"1983","unstructured":"Messina M, Manieri C, Biffignandi P, Massucchetti C, Novi RF, Molinatti GM (1983) Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism. J Endocrinol Investig 6:23\u201327","journal-title":"J Endocrinol Investig"},{"key":"466_CR9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejogrb.2006.10.013","volume":"131","author":"D Armanini","year":"2007","unstructured":"Armanini D, Castello R, Scaroni C, Bonanni G, Faccini G, Pellati D, Bertoldo A, Fiore C, Moghetti P (2007) Treatment of polycystic ovary syndrome with spironolactone plus licorice. Eur J Obstet Gynecol Reprod Biol 131:61\u201367","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"466_CR10","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1056\/NEJMra041536","volume":"352","author":"DA Ehrmann","year":"2005","unstructured":"Ehrmann DA (2005) Polycystic ovary syndrome. N Engl J Med 352:1223\u20131226","journal-title":"N Engl J Med"},{"key":"466_CR11","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.steroids.2012.02.010","volume":"77","author":"D Armanini","year":"2012","unstructured":"Armanini D, Bordin L, Don\u00e0 G, Sabbadin C, Bakdounes L, Ragazzi E, Giorgino FL, Fiore C (2012) Polycystic ovary syndrome: implications of measurement of plasma aldosterone, renin activity and progesterone. Steroids 77:655\u2013658","journal-title":"Steroids"},{"key":"466_CR12","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1210\/jc.2006-0399","volume":"91","author":"T Cascella","year":"2006","unstructured":"Cascella T, Palomba S, Tauchmanov\u00e0 L, Manguso F, Di Biase S, Labella D, Giallauria F, Vigorito C, Colao A, Lombardi G, Orio F (2006) Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. J Clin Endocrinol Metabol 91:4395\u20134400","journal-title":"J Clin Endocrinol Metabol"},{"key":"466_CR13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1210\/jcem-66-1-208","volume":"66","author":"EL Helfer","year":"1988","unstructured":"Helfer EL, Miller JL, Rose LI (1988) Side-effects of spironolactone therapy in the hirsute woman. J Clin Endocrinol Metabol 66:208\u2013211","journal-title":"J Clin Endocrinol Metabol"},{"key":"466_CR14","unstructured":"Smals AGH, Kloppenborg PWC, Hoefnagels WH, Drayer JIM, Benraad ThJ (1978) Pituitary and gonadal function in high-dose spironolactone-treated premenopausal women. Aldosterone antagonists in clinical medicine. Proceedings of the Searle symposium, Nice 303\u2013307"},{"key":"466_CR15","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1210\/jcem-47-3-691","volume":"47","author":"HP Shane","year":"1978","unstructured":"Shane HP, Potts GO (1978) Oral progestational activity of spironolactone. J Clin Endocrinol Metabol 47:691\u2013694","journal-title":"J Clin Endocrinol Metabol"},{"key":"466_CR16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2125.1983.tb01470.x","volume":"15","author":"MD Fernandez","year":"1983","unstructured":"Fernandez MD, Carter GD, Palmer TN (1983) The interaction of canrenone with oestrogen and progesterone receptors in human uterine cytosol. Br J Clin Pharmacol 15:95\u2013101","journal-title":"Br J Clin Pharmacol"},{"key":"466_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bcr.11.2011.5238","author":"S Sundar","year":"2012","unstructured":"Sundar S, Dickinson PD (2012) Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate. BMJ Case Reports. doi: 10.1136\/bcr.11.2011.5238","journal-title":"BMJ Case Reports"},{"key":"466_CR18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1677\/joe.0.0840371","volume":"84","author":"J Levy","year":"1980","unstructured":"Levy J, Burshell A, Marbach M, Afflalo L, Glick SM (1980) Interaction of spironolactone with estradiol receptors in cytosol. J Endocrinol 84:371\u2013379","journal-title":"J Endocrinol"},{"key":"466_CR19","first-page":"1250","volume":"84","author":"P Moghetti","year":"1999","unstructured":"Moghetti P, Castello R, Zamberlan N, Rossini M, Gatti D, Negri C, Tosi F, Muggeo M, Adami S (1999) Spironolactone, but not flutamide, administration prevents bone loss in hyperandrogenic women treated with gonadotropin-releasing hormone agonist. J Clin Endocrinol Metabol 84:1250\u20131254","journal-title":"J Clin Endocrinol Metabol"},{"key":"466_CR20","first-page":"19","volume":"81","author":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group","year":"2004","unstructured":"Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19\u201325","journal-title":"Fertil Steril"},{"key":"466_CR21","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1517\/14656566.2014.896901","volume":"15","author":"D Armanini","year":"2014","unstructured":"Armanini D, Sabbadin C, Don\u00e0 G, Clari G, Bordin L (2014) Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs. Expert Opin Pharmacother 15:909\u2013912","journal-title":"Expert Opin Pharmacother"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-016-0466-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-016-0466-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-016-0466-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T13:28:18Z","timestamp":1567776498000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-016-0466-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,12]]},"references-count":21,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["466"],"URL":"https:\/\/doi.org\/10.1007\/s40618-016-0466-0","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,12]]}}}